Patents by Inventor Lopa Bhatt

Lopa Bhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10898471
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 26, 2021
    Assignee: CELLTAXIS, LLC
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Publication number: 20200138791
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: June 17, 2019
    Publication date: May 7, 2020
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Patent number: 10385007
    Abstract: This present disclosure is directed to compounds of formula (I): where r, q, R1a, R1b, R1c, R1d, R1e, R2, R3, R4a, R5a, R5b, R6a, R6b, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 20, 2019
    Assignee: Celtaxsys, Inc.
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Patent number: 10350197
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 16, 2019
    Assignee: Celtaxsys, Inc.
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Publication number: 20190161471
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R3, Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Inventors: Kurt Roinestad, William Guilford, Thomas Kirkland, Lopa Bhatt, Eric B. Springman
  • Publication number: 20190161437
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R1b, R1c, R1d, R1c, R3, R4a, R4c, R4d, R6, R7, and R8 are described herein as , single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Inventors: Kurt Roinestad, William Guilford, Thomas Kirkland, Lopa Bhatt, Eric B. Springman
  • Patent number: 10202362
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R3, Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 12, 2019
    Assignee: Celtaxsys, Inc.
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Patent number: 10202334
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R1b, R1c, R1d, R1e, R3, R4a, R4b, R4c, R4d, R6, R7, and R8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: February 12, 2019
    Assignee: Celtaxsys, Inc.
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Publication number: 20180162836
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R3, Y, and Z are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Publication number: 20180162802
    Abstract: This present disclosure is directed to compounds of formula (I): where r, q, R1a, R1b, R1c, R1d, R1e, R2, R3, R4a, R5a, R5b, R6a, R6b, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Publication number: 20180162804
    Abstract: This present disclosure is directed to compounds of formula (I): where R1a, R1b, R1c, R1d, R1e, R3, R4a, R4b, R4c, R4d, R6, R7, and R8 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions including the compounds described herein and methods of preparing the compounds described herein are also provided.
    Type: Application
    Filed: December 11, 2017
    Publication date: June 14, 2018
    Inventors: Kurt Roinestad, William Guilford, Tom Kirkland, Lopa Bhatt, Eric Springman
  • Publication number: 20180117014
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 3, 2018
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Publication number: 20180022793
    Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.
    Type: Application
    Filed: April 6, 2017
    Publication date: January 25, 2018
    Inventors: Hyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner
  • Patent number: 9820974
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Grant
    Filed: September 10, 2015
    Date of Patent: November 21, 2017
    Assignee: Celtaxsys, Inc.
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Patent number: 9617330
    Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: April 11, 2017
    Assignee: Celtaxsys, Inc.
    Inventors: Hyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner
  • Publication number: 20160199470
    Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 14, 2016
    Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
  • Publication number: 20160067226
    Abstract: The present invention is directed to methods of inhibiting LTA4-h in a human patient and method of treating a condition ameliorated by the inhibition of leukotriene A4 hydrolase activity in a human patient comprising administering to said human patient the compound, 4-{5-[4-(4-Oxazol-2-yl-phenoxy)-benzyl]-2,5-diaza-bicyclo[2.2.1]hept-2-ylmethyl}-benzoic acid.
    Type: Application
    Filed: September 10, 2015
    Publication date: March 10, 2016
    Inventors: Eric B. Springman, Margaret McCrann Pugh, Lopa Bhatt, Ralph Grosswald
  • Publication number: 20140294862
    Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
    Type: Application
    Filed: March 20, 2014
    Publication date: October 2, 2014
    Applicant: Celtaxsys, Inc.
    Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
  • Patent number: 8715654
    Abstract: The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.
    Type: Grant
    Filed: October 2, 2009
    Date of Patent: May 6, 2014
    Assignee: Celtaxsys, Inc.
    Inventors: Surendra Chavan, Jonathan L. Moon, Lopa Bhatt
  • Publication number: 20100203087
    Abstract: The present invention provides compositions and methods of controlling the direction and/or movement of migratory cells. Specifically, the invention is directed to the identification of novel chemorepellents and unimodal fugetaxins, their agonists and antagonists which alter or affect the movement of cells involved in immune, inflammatory or cancerous phenotypes.
    Type: Application
    Filed: February 2, 2010
    Publication date: August 12, 2010
    Inventors: Hyun Kang, Scott Sacane, Jonathan L. Moon, Erica B. Goodhew, Lopa Bhatt, Stacey L. Rose, Milton H. Werner